Nephrol Dial Transplant (2003) 18: 2314-2320
Original Article
No effect of enalapril on progression in autosomal dominant polycystic kidney disease
1Department of Nephrology, 2Clinical Genetic Center, 3Clinical Chemical Laboratory and 4Department of General Internal Medicine and Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands
Correspondence and offprint requests to: Professor M. H. Breuning, Clinical Genetic Center, Leiden University Medical Center, Albinusdreef 2, PO Box 9600, 2300 RC Leiden, The Netherlands. Email: M.H.Breuning{at}lumc.nl
Background. Angiotensin-converting enzyme (ACE) inhibitors are capable of reducing proteinuria and microalbuminuria with preservation of renal function in diabetic and non-diabetic renal disease. We designed a study investigating the effect of enalapril on the protection of renal function in autosomal dominant polycystic kidney disease (ADPKD).
Methods. We studied 61 normotensive and 28 hypertensive ADPKD patients. The normotensive group participated in a randomized double-blind placebo-controlled study, using enalapril. The hypertensive group was randomized for open label treatment with enalapril or the ß-blocker atenolol. The follow-up was 3 years, and renal function was established repetitively by measuring the clearance of inulin.
Results. In the normotensive group, renal function at baseline was 112 ± 3 ml/min and decreased by -8 ± 2 ml/min (P < 0.001). The loss of renal function in the patients treated with enalapril or placebo was similar (-7 ± 3 vs -9 ± 1 ml/min; P = 0.4). Although blood pressure significantly decreased with enalapril treatment, it had no effect on microalbuminuria. In the hypertensive group, renal function at baseline was 89 ± 2 ml/min. The mean decline in renal function was -12 ± 2 ml/min (P < 0.001), and was equal in patients treated with enalapril and those treated with atenolol. The patients treated with atenolol required more additional treatment to control blood pressure, but no difference on microalbuminuria was observed between the two treatments.
Conclusion. This study was unable to detect a beneficial effect of ACE inhibition on loss of renal function in ADPKD patients.
Keywords: ACE inhibition; ADPKD; GFR; progression; randomized trial
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R. Zeltner, R. Poliak, B. Stiasny, R. E. Schmieder, and B. D. Schulze Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease Nephrol. Dial. Transplant., February 1, 2008; 23(2): 573 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. R Lawson, T. W Doulton, and G. A MacGregor Review: Autosomal Dominant Polycystic Kidney Disease: Role of the Renin-Angiotensin System in Raised Blood Pressure in Progression of Renal and Cardiovascular Disease Journal of Renin-Angiotensin-Aldosterone System, September 1, 2006; 7(3): 139 - 145. [Abstract] [PDF]
|
|
|
|
 |
|
 R. Perrone Imaging Progression in Polycystic Kidney Disease N. Engl. J. Med., May 18, 2006; 354(20): 2181 - 2183. [Full Text] [PDF]
|
|